SCHEMBL12061289

SCHEMBL12061289

CC1OC(CO)C(O)C(OC2OC(CO)C(O)C(O)C2O)C1C

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ AMY1A P0DUB6 1/20 0.47
▸ LGALS8 O00214 1/20 0.47
▸ LGALS3 P17931 1/20 0.47
▸ LGALS4 P56470 1/20 0.47
▸ PTPN1 P18031 1/20 0.47
▸ GJA1 P17302 1/20 0.46
▸ GJB2 P29033 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ IGF2R P11717 2/20 0.45
▸ SELE P16581 1/20 0.45
▸ MAPT P10636 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15087217 1.00 MEN1 (0.51) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL16868390 1.00 MEN1 (0.51) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL12787207 1.00 MEN1 (0.51) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL20306014 0.92 MEN1 (0.50) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL19889807 0.90 MEN1 (0.54) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL12787189 0.89 LGALS8 (0.52) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL12787186 0.89 LGALS8 (0.52) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL10136109 0.89 LGALS8 (0.52) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL12787180 0.89 LGALS8 (0.52) MEN1KMT2AAMY1ALGALS8LGALS3
SCHEMBL769291 0.89 LGALS8 (0.52) MEN1KMT2AAMY1ALGALS8LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150064240-A1 MUC1 Based Glycolipopeptide Vaccine with Adjuvant ONCOTHYREON INC. 2015-03-05 — — US disclosed
US-8889616-B2 MUC1 based glycolipopeptide vaccine with adjuvant ONCOTHYREON INC. (US) 2014-11-18 — — US disclosed
US-8802841-B2 1,2-dideoxy-1,2-diamino oligosaccharides and polysaccharides and derivatives thereof GLYCOM A/S (DK) 2014-08-12 — — US disclosed
US-8802841-B2 1,2-dideoxy-1,2-diamino oligosaccharides and polysaccharides and derivatives thereof GLYCOM A/S (DK) 2014-08-12 — — US disclosed
US-8329639-B2 MUC1 based glycolipopeptide vaccine with adjuvant ONCOTHYREON INC. (US) 2012-12-11 — — US disclosed
US-20120282329-A1 MUC1 Based Glycolipopeptide Vaccine with Adjuvant ONCOTHYREON INC. (US) 2012-11-08 — — US disclosed
US-20120219617-A1 MUC1 Based Glycolipopeptide Vaccine with Adjuvant ONCOTHYREON INC. (US) 2012-08-30 — — US disclosed
US-20110060139-A1 CARBOHYDRATE DERIVATIVES GLYCOM A/S (DK) 2011-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282329-A1 MUC1 Based Glycolipopeptide Vaccine with Adjuvant MUC1, LGALS3BP, ST3GAL3 MEN1 670/4885KMT2A 2399/4885AMY1A 3291/4885
US-20150064240-A1 MUC1 Based Glycolipopeptide Vaccine with Adjuvant MUC1, LGALS3BP, ST3GAL3 MEN1 670/4885KMT2A 2399/4885AMY1A 3291/4885
US-20110060139-A1 CARBOHYDRATE DERIVATIVES ALG1, MAN2A1, MAN1B1 MEN1 131/4885KMT2A 2534/4885AMY1A 98/4885
US-20120219617-A1 MUC1 Based Glycolipopeptide Vaccine with Adjuvant MUC1, LGALS3BP, ST3GAL3 MEN1 670/4885KMT2A 2399/4885AMY1A 3291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback